Who Paid My Doc
Lung Cancer Combo Study
Research payments
$1,119,397
Through program year 2024, $1,119,397 in research payments was reported against Lung Cancer Combo Study, across 8 payments, paid by Novartis Pharmaceuticals Corporation.
- Paid by
- Novartis Pharmaceuticals Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $29,378 | 1 |
| 2023 | Research | $182,691 | 2 |
| 2022 | Research | $316,020 | 1 |
| 2021 | Research | $254,458 | 1 |
| 2020 | Research | $228,439 | 2 |
| 2019 | Research | $108,412 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
2 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.